Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in the inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies, and solid tumors. The abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.
Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
Bosutinib is an aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methyl piperazine-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a nitrile, N-methyl piperazine, an aromatic ether, a tertiary amino compound, an aminoquinoline, and a dichlorobenzene.
Bosutinib Monohydrate is the monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in the inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies, and solid tumors. The abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.
Mechanism of Action
Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and the Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumor has been observed following the administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells.
Indications
- Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
- Bosulif is indicated for the treatment of adult patients with newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.
- Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury.
- Myeloid Leukemia, Chronic, Chronic Phase
- Blast phase Chronic myelocytic leukemia
- Refractory, accelerated phase Chronic myelogenous leukemia
Use in Cancer
Bosutinib is approved to treat:
- Chronic myelogenous leukemia (CML) is Philadelphia chromosome positive. It is used:
- In adults with newly diagnosed chronic phase CML. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that bosutinib provides a clinical benefit in these patients.
- In adults with chronic phase, accelerated phase, or blastic phase CML that cannot be treated with or that did not respond to other treatments.
Bosutinib is also being studied in the treatment of other types of cancer.
Contraindication
- are allergic to bosutinib or any ingredients of the medication
- have a history of irregular heartbeat, particularly long QT syndrome
- have reduced liver function
- have untreated low potassium or low magnesium in your blood
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- fluid in the covering of the heart or pericardium
- chronic heart failure
- escape of fluid into the lungs
- fluid in the lungs
- liver problems
- fluid retention in the legs, feet, arms or hands
- high amount of bilirubin in the blood
- excessive diarrhea
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- reactivation of hepatitis B infection
- chronic kidney disease stage 3A (moderate)
- chronic kidney disease stage 3B (moderate)
- chronic kidney disease stage 4 (severe)
- Child-Pugh class A liver impairment
- Child-Pugh class B liver impairment
- Child-Pugh class C liver impairment
Dosage
Strengths: 100 mg; 500 mg; 400 mg
Chronic Myelogenous Leukemia
Newly-diagnosed:
- 400 mg orally once daily
- Duration of therapy: Until disease progression or patient intolerance
Chronic/accelerated/blast phase:
- 500 mg orally once daily
- Duration of therapy: Until disease progression or patient intolerance
- Take this drug with food.
- If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day.
Renal Dose Adjustments
RECOMMENDED STARTING DOSE for newly-diagnosed chronic phase Ph+ CML:
- Normal renal function: 400 mg orally once a day
- Moderate renal dysfunction (CrCl 30 to 50 mL/min): 300 mg orally once a day
- Severe renal dysfunction (CrCl less than 30 mL/min): 200 mg orally once a day
RECOMMENDED STARTING DOSE for Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy:
- Normal renal function: 500 mg orally once a day
- Moderate renal dysfunction (CrCl 30 to 50 mL/min): 400 mg orally once a day
- Severe renal dysfunction (CrCl less than 30 mL/min): 300 mg orally once a day
Liver Dose Adjustments
RECOMMENDED STARTING DOSE for newly-diagnosed chronic phase Ph+ CML:
- Normal liver function: 400 mg orally once a day
- Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): 200 mg orally once a day (There are no clinical data for efficacy at the dose of 200 mg once daily in patients with CML)
RECOMMENDED STARTING DOSE for Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy:
- Normal liver function: 500 mg orally once a day
- Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): 200 mg orally once a day (There are no clinical data for efficacy at the dose of 200 mg once daily in patients with CML)
Dose Adjustments
DOSE ESCALATION:
- The dose can be escalated by increments of 100 mg once daily to a maximum of 600 mg once daily in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response and who did not have Grade 3 or higher adverse reactions at the recommended starting dosage.
NON-HEMATOLOGIC ADVERSE REACTIONS:
Elevated liver transaminases:
- Liver transaminases greater than 5 times the institutional upper limit of normal (ULN): Withhold therapy until recovery to less than or equal to 2.5 x ULN and resume at 400 mg orally once daily thereafter. If recovery takes longer than 4 weeks, discontinue therapy.
- Liver transaminases greater than or equal to 3 x ULN concurrently with bilirubin greater than 2 x ULN and alkaline phosphatase less than 2 x ULN (Hy’s law case definition): Discontinue therapy
Diarrhea:
- For NCI CTCAE Grade 3 to 4 diarrhea (an increase of greater than or equal to 7 stools/day over baseline/pretreatment): Withhold therapy until recovery to Grade 1 or less. Treatment may be resumed at 400 mg orally once a day.
Other Moderate or Severe Non-Hematologic Adverse Reactions:
- Withhold therapy until resolved, then consider resuming therapy at a dose reduced by 100 mg orally once a day.
- If appropriate, consider re-escalating the dose to the starting dose once a day.
- Doses less than 300 mg/day have been used in patients; however, efficacy has not been established
MYELOSUPPRESSION:
- Absolute neutrophil count (ANC) less than 1000 x 10(6)/L OR platelets less than 50,000 x 10(6)/L: Withhold therapy until ANC is greater than or equal to 1000 x 10(6)/L AND platelets are greater than or equal to 50,000 x 10(6)/L.
- Resume therapy at the same dose if recovery occurs within 2 weeks. If blood counts remain low for more than 2 weeks, upon recovery, reduce the dose by 100 mg and resume therapy.
- If cytopenia recurs, reduce the dose by an additional 100 mg upon recovery and resume therapy.
- Doses less than 300 mg/day have been used in patients; however, efficacy has not been established.
Side Effects
The Most Common
- headache
- loss of appetite
- tiredness or weakness
- change in the ability to taste food
- ringing in the ears
- nausea
- vomiting
- diarrhea
- sudden stomach area pain
- unexplained bleeding or bruising
- blood in urine or stool
- change in the frequency of urination
- increase or decrease in the amount of urine
- dizziness
- fever, sore throat, chills, or other signs of infection
- shortness of breath and cough
- chest pain
- swelling of the face, hands, ankles, feet, or lower legs
- sudden weight gain
- yellowing of the skin and eyes
- dark or tea-colored urine
- hives
- rash
- itching
- difficulty breathing or swallowing
More Common
- abnormal heart rhythms (such as fast or slow heart rate, palpitations), fainting, or seizures
- chest pain
- dizziness
- fever
- generalized pain (back pain, muscle pain)
- increased blood pressure
- shortness of breath
- changed sense of taste
- cold symptoms (e.g., sore throat, runny nose)
- decreased appetite
- diarrhea
- fatigue
- flu-like symptoms (sudden lack of energy, fever, cough, sore throat)
Rare
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
- signs of breathing problems (e.g., shortness of breath, troubled breathing, wheezing, or tightness in chest, fast or irregular breathing)
- signs of dehydration (e.g., decreased urine, dry skin, dry and sticky mouth, sleepiness, dizziness, headache, thirst, confusion)
- signs of fluid build-up around the lungs (e.g., chest pain, cough, hiccups, rapid breathing)
- signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
- signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain)
- signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
- signs of pneumonia (e.g., fever, chills, shortness of breath, cough)
- swelling of the hands, feet, or face
- symptoms of fluid build-up around the heart (e.g., fever, fatigue, muscle aches, shortness of breath, nausea, vomiting, diarrhea, fast or pounding heartbeat, light-headedness)
- symptoms of inflammation of the tissue surrounding the heart (pericarditis; e.g., chest pain, cough, fast or irregular heartbeat, shortness of breath, weakness, or fatigue)
- symptoms of respiratory failure (e.g., dizziness, trouble breathing, shortness of breath, fast, shallow breathing, wheezing, bluish coloration to the skin and lips from lack of oxygen)
- symptoms of too little phosphorus in the blood (e.g., muscle weakness, fatigue, bone pain, fractures, numbness, confusion)
- symptoms of too much potassium in the body (e.g., muscle fatigue, weakness, difficulty moving, abnormal heart rhythms, nausea)
- signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat)
- signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort
- signs of bleeding in the stomach (e.g., bloody, black, or tarry stools, spitting up of blood, vomiting blood or material that looks like coffee grounds)
Drug Interactions
| DRUG | INTERACTION |
|---|---|
| Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Bosutinib. |
| Abametapir | The serum concentration of Bosutinib can be increased when it is combined with Abametapir. |
| Abatacept | The metabolism of Bosutinib can be increased when combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Bosutinib. |
| Abemaciclib | The metabolism of Abemaciclib can be decreased when combined with Bosutinib. |
| Abrocitinib | The serum concentration of Bosutinib can be increased when it is combined with Abrocitinib. |
| Acalabrutinib | The metabolism of Bosutinib can be decreased when combined with Acalabrutinib. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Bosutinib. |
| Acetaminophen | The metabolism of Bosutinib can be increased when combined with Acetaminophen. |
| Acetazolamide | The metabolism of Bosutinib can be decreased when combined with Acetazolamide. |
| Acetylsalicylic acid | The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bosutinib. |
| Adalimumab | The metabolism of Bosutinib can be increased when combined with Adalimumab. |
| Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bosutinib. |
| Afatinib | The serum concentration of Bosutinib can be increased when it is combined with Afatinib. |
| Albendazole | The metabolism of Bosutinib can be decreased when combined with Albendazole. |
| Aldesleukin | The metabolism of Bosutinib can be decreased when combined with Aldesleukin. |
| Alectinib | The metabolism of Alectinib can be decreased when combined with Bosutinib. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Bosutinib. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Bosutinib. |
| Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bosutinib. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Bosutinib. |
| Almasilate | Almasilate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Almotriptan | The metabolism of Almotriptan can be decreased when combined with Bosutinib. |
| Alpelisib | The metabolism of Bosutinib can be increased when combined with Alpelisib. |
| Alprazolam | The metabolism of Alprazolam can be decreased when combined with Bosutinib. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Bosutinib. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Bosutinib. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ambrisentan | The serum concentration of Bosutinib can be increased when it is combined with Ambrisentan. |
| Aminoglutethimide | The metabolism of Bosutinib can be increased when combined with Aminoglutethimide. |
| Aminophenazone | The metabolism of Aminophenazone can be decreased when combined with Bosutinib. |
| Aminophylline | The metabolism of Aminophylline can be decreased when combined with Bosutinib. |
| Amiodarone | The serum concentration of Bosutinib can be increased when it is combined with Amiodarone. |
| Amitriptyline | The metabolism of Amitriptyline can be decreased when combined with Bosutinib. |
| Amobarbital | The metabolism of Bosutinib can be increased when combined with Amobarbital. |
| Amodiaquine | The metabolism of Amodiaquine can be decreased when combined with Bosutinib. |
| Amprenavir | The metabolism of Bosutinib can be decreased when combined with Amprenavir. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Bosutinib. |
| Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Bosutinib. |
| Anakinra | The metabolism of Bosutinib can be increased when combined with Anakinra. |
| Anastrozole | The metabolism of Anastrozole can be decreased when combined with Bosutinib. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Bosutinib. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Bosutinib. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bosutinib. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Bosutinib. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Bosutinib is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | The metabolism of Antipyrine can be decreased when combined with Bosutinib. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bosutinib. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bosutinib. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bosutinib. |
| Apalutamide | The serum concentration of Bosutinib can be decreased when it is combined with Apalutamide. |
| Apixaban | The metabolism of Apixaban can be decreased when combined with Bosutinib. |
| Apomorphine | The metabolism of Apomorphine can be decreased when combined with Bosutinib. |
| Apremilast | The metabolism of Bosutinib can be increased when combined with Apremilast. |
| Aprepitant | The metabolism of Bosutinib can be decreased when combined with Aprepitant. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Bosutinib. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Bosutinib. |
| Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Bosutinib. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be decreased when combined with Bosutinib. |
| Armodafinil | The metabolism of Bosutinib can be increased when combined with Armodafinil. |
| Arsenic trioxide | The serum concentration of Bosutinib can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Articaine. |
| Asciminib | The serum concentration of Bosutinib can be increased when it is combined with Asciminib. |
| Asenapine | Asenapine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Astemizole | The metabolism of Bosutinib can be decreased when combined with Astemizole. |
| COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bosutinib. |
| Asunaprevir | The serum concentration of Bosutinib can be increased when it is combined with Asunaprevir. |
| Atazanavir | The metabolism of Bosutinib can be decreased when combined with Atazanavir. |
| Atorvastatin | The metabolism of Atorvastatin can be decreased when combined with Bosutinib. |
| Avacopan | The metabolism of Bosutinib can be decreased when combined with Avacopan. |
| Avanafil | The serum concentration of Avanafil can be increased when it is combined with Bosutinib. |
| Avatrombopag | The serum concentration of Bosutinib can be increased when it is combined with Avatrombopag. |
| Axitinib | The metabolism of Axitinib can be decreased when combined with Bosutinib. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Bosutinib. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Bosutinib. |
| Azelastine | The metabolism of Azelastine can be decreased when combined with Bosutinib. |
| Azithromycin | The metabolism of Bosutinib can be decreased when combined with Azithromycin. |
| Bacillus calmette | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bosutinib. |
| Bacillus calmette | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bosutinib. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bosutinib. |
| Baricitinib | The risk or severity of adverse effects can be increased when Bosutinib is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bosutinib. |
| BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Bosutinib. |
| Beclomethasone dipropionate | The metabolism of Bosutinib can be increased when combined with Beclomethasone dipropionate. |
| Belantamab mafodotin | The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin. |
| Belatacept | The risk or severity of adverse effects can be increased when Bosutinib is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Bosutinib. |
| Belumosudil | The serum concentration of Bosutinib can be increased when it is combined with Belumosudil. |
| Belzutifan | The serum concentration of Bosutinib can be decreased when it is combined with Belzutifan. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Bosutinib. |
| Bendamustine | The risk or severity of adverse effects can be increased when Bosutinib is combined with Bendamustine. |
| Bendroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bosutinib. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Benzocaine. |
| Benzthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bosutinib. |
| Betamethasone | The metabolism of Bosutinib can be increased when combined with Betamethasone. |
| Betamethasone phosphate | The metabolism of Bosutinib can be increased when combined with Betamethasone phosphate. |
| Betrixaban | The serum concentration of Bosutinib can be increased when it is combined with Betrixaban. |
| Bexarotene | The metabolism of Bosutinib can be increased when combined with Bexarotene. |
| Bicalutamide | The metabolism of Bosutinib can be decreased when combined with Bicalutamide. |
| Bifonazole | The metabolism of Bosutinib can be decreased when combined with Bifonazole. |
| Bimekizumab | The metabolism of Bosutinib can be increased when combined with Bimekizumab. |
| Bismuth subnitrate | Bismuth subnitrate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisoprolol | The serum concentration of Bosutinib can be increased when it is combined with Bisoprolol. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Bosutinib. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Bosutinib. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Blinatumomab. |
| Boceprevir | The metabolism of Bosutinib can be decreased when combined with Boceprevir. |
| Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Bosutinib. |
| Bortezomib | The metabolism of Bortezomib can be decreased when combined with Bosutinib. |
| Bosentan | The metabolism of Bosutinib can be increased when combined with Bosentan. |
| Brentuximab vedotin | The metabolism of Brentuximab vedotin can be decreased when combined with Bosutinib. |
| Brigatinib | The metabolism of Brigatinib can be decreased when combined with Bosutinib. |
| Brodalumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Brodalumab. |
| Budesonide | The metabolism of Bosutinib can be increased when combined with Budesonide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Bupivacaine. |
| Buprenorphine | The metabolism of Bosutinib can be decreased when combined with Buprenorphine. |
| Busulfan | The metabolism of Busulfan can be decreased when combined with Bosutinib. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Butacaine. |
| Butalbital | The metabolism of Bosutinib can be increased when combined with Butalbital. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Butamben. |
| Cabazitaxel | The metabolism of Cabazitaxel can be decreased when combined with Bosutinib. |
| Cabergoline | The metabolism of Cabergoline can be decreased when combined with Bosutinib. |
| Calcitriol | The metabolism of Bosutinib can be increased when combined with Calcitriol. |
| Calcium carbonate | Calcium carbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Canagliflozin | The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin. |
| Canakinumab | The metabolism of Bosutinib can be increased when combined with Canakinumab. |
| Candicidin | The metabolism of Bosutinib can be decreased when combined with Candicidin. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Bosutinib. |
| Cannabidiol | The metabolism of Bosutinib can be decreased when combined with Cannabidiol. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Bosutinib. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bosutinib. |
| Capmatinib | The serum concentration of Bosutinib can be increased when it is combined with Capmatinib. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Capsaicin. |
| Carbamazepine | The metabolism of Bosutinib can be increased when combined with Carbamazepine. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Bosutinib. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Bosutinib. |
| Carfilzomib | The serum concentration of Bosutinib can be increased when it is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Bosutinib. |
| Carvedilol | The serum concentration of Bosutinib can be increased when it is combined with Carvedilol. |
| Cefradine | The metabolism of Bosutinib can be increased when combined with Cefradine. |
| Celecoxib | The metabolism of Celecoxib can be decreased when combined with Bosutinib. |
| Cenobamate | The serum concentration of Bosutinib can be decreased when it is combined with Cenobamate. |
| Cephalexin | The metabolism of Bosutinib can be decreased when combined with Cephalexin. |
| Ceritinib | The metabolism of Bosutinib can be decreased when combined with Ceritinib. |
| Cerivastatin | The metabolism of Bosutinib can be increased when combined with Cerivastatin. |
| Certolizumab pegol | The metabolism of Bosutinib can be increased when combined with Certolizumab pegol. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bosutinib. |
| Chloramphenicol | The metabolism of Bosutinib can be decreased when combined with Chloramphenicol. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Chloroprocaine. |
| Chloroquine | The metabolism of Chloroquine can be decreased when combined with Bosutinib. |
| Chlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bosutinib. |
| Chlorpromazine | The metabolism of Bosutinib can be increased when combined with Chlorpromazine. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bosutinib. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Bosutinib. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Cinchocaine. |
| Ciprofloxacin | The metabolism of Bosutinib can be decreased when combined with Ciprofloxacin. |
| Cisapride | The metabolism of Bosutinib can be decreased when combined with Cisapride. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib. |
| Citalopram | The metabolism of Bosutinib can be decreased when combined with Citalopram. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Bosutinib. |
| Clarithromycin | The serum concentration of Bosutinib can be increased when it is combined with Clarithromycin. |
| Clevidipine | The metabolism of Bosutinib can be increased when combined with Clevidipine. |
| Clobazam | The metabolism of Bosutinib can be increased when combined with Clobazam. |
| Clobetasol propionate | The metabolism of Bosutinib can be increased when combined with Clobetasol propionate. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bosutinib. |
| Clofazimine | The serum concentration of Bosutinib can be increased when it is combined with Clofazimine. |
| Clofibrate | The metabolism of Bosutinib can be increased when combined with Clofibrate. |
| Clomifene | The serum concentration of Bosutinib can be increased when it is combined with Clomifene. |
| Clomipramine | The metabolism of Clomipramine can be decreased when combined with Bosutinib. |
| Clonidine | The metabolism of Clonidine can be decreased when combined with Bosutinib. |
| Clopidogrel | The risk or severity of bleeding can be increased when Clopidogrel is combined with Bosutinib. |
| Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib. |
| Clozapine | The risk or severity of neutropenia can be increased when Bosutinib is combined with Clozapine. |
| Cobicistat | The serum concentration of Bosutinib can be increased when it is combined with Cobicistat. |
| Cobimetinib | The metabolism of Cobimetinib can be decreased when combined with Bosutinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Cocaine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Bosutinib. |
| Conivaptan | The serum concentration of Bosutinib can be increased when it is combined with Conivaptan. |
| Copanlisib | The metabolism of Copanlisib can be decreased when combined with Bosutinib. |
| Corticotropin | The metabolism of Bosutinib can be increased when combined with Corticotropin. |
| Cortisone acetate | The metabolism of Bosutinib can be increased when combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib. |
| Crizotinib | The serum concentration of Bosutinib can be increased when it is combined with Crizotinib. |
| Curcumin | The serum concentration of Bosutinib can be increased when it is combined with Curcumin. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bosutinib. |
| Cyclopenthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bosutinib. |
| Cyclophosphamide | The metabolism of Bosutinib can be increased when combined with Cyclophosphamide. |
| Cyclosporine | Bosutinib may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bosutinib. |
| Cyproterone acetate | The metabolism of Bosutinib can be decreased when combined with Cyproterone acetate. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Bosutinib. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Bosutinib. |
| Dabrafenib | The serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bosutinib. |
| Daclatasvir | The serum concentration of Bosutinib can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Bosutinib can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bosutinib. |
| Dalfopristin | The metabolism of Bosutinib can be decreased when combined with Dalfopristin. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Bosutinib. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Bosutinib. |
| Danazol | The metabolism of Bosutinib can be decreased when combined with Danazol. |
| Dapsone | The metabolism of Dapsone can be decreased when combined with Bosutinib. |
| Daptomycin | The serum concentration of Bosutinib can be increased when it is combined with Daptomycin. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bosutinib. |
| Darolutamide | The serum concentration of Bosutinib can be increased when it is combined with Darolutamide. |
| Darunavir | The serum concentration of Bosutinib can be increased when it is combined with Darunavir. |
| Dasabuvir | The metabolism of Dasabuvir can be decreased when combined with Bosutinib. |
| Dasatinib | The metabolism of Bosutinib can be decreased when combined with Dasatinib. |
| Daunorubicin | The metabolism of Bosutinib can be decreased when combined with Daunorubicin. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Bosutinib. |
| Deferasirox | The metabolism of Bosutinib can be increased when combined with Deferasirox. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Bosutinib. |
| Deflazacort | The metabolism of Bosutinib can be increased when combined with Deflazacort. |
| Delavirdine | The metabolism of Bosutinib can be decreased when combined with Delavirdine. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Bosutinib. |
| Desipramine | The metabolism of Bosutinib can be decreased when combined with Desipramine. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Bosutinib. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bosutinib. |
| Desvenlafaxine | The metabolism of Bosutinib can be decreased when combined with Desvenlafaxine. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Bosutinib is combined with Deucravacitinib. |
| Dexamethasone | The metabolism of Bosutinib can be increased when combined with Dexamethasone. |
| Dexamethasone acetate | The serum concentration of Bosutinib can be decreased when it is combined with Dexamethasone acetate. |
| Dexibuprofen | The metabolism of Dexibuprofen can be decreased when combined with Bosutinib. |
| Dexlansoprazole | Dexlansoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bosutinib. |
| Dextran | The risk or severity of bleeding can be increased when Dextran is combined with Bosutinib. |
| Dextropropoxyphene | The metabolism of Bosutinib can be decreased when combined with Dextropropoxyphene. |
| Diclofenac | The metabolism of Diclofenac can be decreased when combined with Bosutinib. |
| Dicloxacillin | The metabolism of Bosutinib can be increased when combined with Dicloxacillin. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Bosutinib. |
| Diethylstilbestrol | The metabolism of Bosutinib can be decreased when combined with Diethylstilbestrol. |
| Difluocortolone | The metabolism of Bosutinib can be increased when combined with Difluocortolone. |
| Digitoxin | The metabolism of Digitoxin can be decreased when combined with Bosutinib. |
| Digoxin | The serum concentration of Bosutinib can be increased when it is combined with Digoxin. |
| Dihydroergocornine | The metabolism of Bosutinib can be decreased when combined with Dihydroergocornine. |
| Dihydroergocristine | The metabolism of Bosutinib can be decreased when combined with Dihydroergocristine. |
| Dihydroergotamine | The metabolism of Bosutinib can be decreased when combined with Dihydroergotamine. |
| Diltiazem | The metabolism of Bosutinib can be decreased when combined with Diltiazem. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Bosutinib is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | The metabolism of Bosutinib can be decreased when combined with Dimethyl sulfoxide. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Dinutuximab. |
| Diosmin | The serum concentration of Bosutinib can be increased when it is combined with Diosmin. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Diphenhydramine. |
| Dipyridamole | The risk or severity of bleeding can be increased when Dipyridamole is combined with Bosutinib. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Bosutinib is combined with Diroximel fumarate. |
| Docetaxel | The metabolism of Bosutinib can be decreased when combined with Docetaxel. |
| Dofetilide | The metabolism of Dofetilide can be decreased when combined with Bosutinib. |
| Dolutegravir | The serum concentration of Bosutinib can be increased when it is combined with Dolutegravir. |
| Domperidone | The metabolism of Domperidone can be decreased when combined with Bosutinib. |
| Doxazosin | The metabolism of Bosutinib can be decreased when combined with Doxazosin. |
| Doxepin | Doxepin can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Doxorubicin | The metabolism of Bosutinib can be decreased when combined with Doxorubicin. |
| Dronabinol | The serum concentration of Dronabinol can be increased when it is combined with Bosutinib. |
| Dronedarone | The serum concentration of Bosutinib can be increased when it is combined with Dronedarone. |
| Drospirenone | The metabolism of Bosutinib can be decreased when combined with Drospirenone. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bosutinib. |
| Duvelisib | The metabolism of Bosutinib can be decreased when combined with Duvelisib. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Dyclonine. |
| Ebastine | The metabolism of Bosutinib can be decreased when combined with Ebastine. |
| Ebola Zaire | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bosutinib. |
| Echinacea | The metabolism of Bosutinib can be increased when combined with Echinacea. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bosutinib. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Bosutinib. |
| Edoxaban | The serum concentration of Bosutinib can be increased when it is combined with Edoxaban. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bosutinib. |
| Efavirenz | The metabolism of Bosutinib can be decreased when combined with Efavirenz. |
| Elagolix | The serum concentration of Bosutinib can be increased when it is combined with Elagolix. |
| Elbasvir | The serum concentration of Bosutinib can be increased when it is combined with Elbasvir. |
| Elexacaftor | The metabolism of Bosutinib can be decreased when combined with Elexacaftor. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Bosutinib. |
| Eltrombopag | The metabolism of Eltrombopag can be decreased when combined with Bosutinib. |
| Elvitegravir | The metabolism of Bosutinib can be decreased when combined with Elvitegravir. |
| Emapalumab | The metabolism of Bosutinib can be increased when combined with Emapalumab. |
| Enasidenib | The serum concentration of Bosutinib can be increased when it is combined with Enasidenib. |
| Enfortumab vedotin | The serum concentration of Bosutinib can be increased when it is combined with Enfortumab vedotin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Bosutinib. |
| Entrectinib | The serum concentration of Bosutinib can be increased when it is combined with Entrectinib. |
| Enzalutamide | The serum concentration of Bosutinib can be decreased when it is combined with Enzalutamide. |
| Epinastine | Epinastine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Epinephrine | The metabolism of Bosutinib can be decreased when combined with Epinephrine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Bosutinib. |
| Epoprostenol | The risk or severity of bleeding can be increased when Epoprostenol is combined with Bosutinib. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Bosutinib. |
| Erdafitinib | The serum concentration of Bosutinib can be increased when it is combined with Erdafitinib. |
| Ergotamine | The metabolism of Bosutinib can be decreased when combined with Ergotamine. |
| Eribulin | The risk or severity of adverse effects can be increased when Bosutinib is combined with Eribulin. |
| Erlotinib | The metabolism of Bosutinib can be decreased when combined with Erlotinib. |
| Ertugliflozin | The serum concentration of Bosutinib can be increased when it is combined with Ertugliflozin. |
| Erythromycin | The serum concentration of Bosutinib can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bosutinib. |
| Esomeprazole | Esomeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estetrol | The metabolism of Bosutinib can be decreased when combined with Estetrol. |
| Estradiol | The metabolism of Estradiol can be decreased when combined with Bosutinib. |
| Estradiol acetate | The metabolism of Bosutinib can be increased when combined with Estradiol acetate. |
| Estradiol benzoate | The metabolism of Bosutinib can be increased when combined with Estradiol benzoate. |
| Estradiol cypionate | The metabolism of Bosutinib can be increased when combined with Estradiol cypionate. |
| Estradiol dienanthate | The metabolism of Bosutinib can be increased when combined with Estradiol dienanthate. |
| Estradiol valerate | The metabolism of Bosutinib can be increased when combined with Estradiol valerate. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Bosutinib. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Bosutinib. |
| Etanercept | The metabolism of Bosutinib can be increased when combined with Etanercept. |
| Ethambutol | The metabolism of Bosutinib can be decreased when combined with Ethambutol. |
| Ethanol | The metabolism of Bosutinib can be increased when combined with Ethanol. |
| Ethinylestradiol | The metabolism of Ethinylestradiol can be decreased when combined with Bosutinib. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Etidocaine. |
| Etoposide | The metabolism of Etoposide can be decreased when combined with Bosutinib. |
| Etoricoxib | The metabolism of Bosutinib can be decreased when combined with Etoricoxib. |
| Etravirine | The metabolism of Bosutinib can be increased when combined with Etravirine. |
| Everolimus | The serum concentration of Bosutinib can be increased when it is combined with Everolimus. |
| Famotidine | Famotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Favipiravir | The serum concentration of Bosutinib can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Bosutinib can be increased when it is combined with Fedratinib. |
| Felbamate | The metabolism of Bosutinib can be increased when combined with Felbamate. |
| Fenofibrate | The metabolism of Bosutinib can be decreased when combined with Fenofibrate. |
| Fentanyl | The metabolism of Fentanyl can be decreased when combined with Bosutinib. |
| Fexinidazole | The metabolism of Bosutinib can be decreased when combined with Fexinidazole. |
| Fexofenadine | The serum concentration of Bosutinib can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Bosutinib can be increased when it is combined with Filgotinib. |
| Finerenone | The serum concentration of Finerenone can be increased when it is combined with Bosutinib. |
| Fingolimod | Bosutinib may increase the immunosuppressive activities of Fingolimod. |
| Flibanserin | The serum concentration of Bosutinib can be increased when it is combined with Flibanserin. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Bosutinib. |
| Flucloxacillin | The metabolism of Bosutinib can be increased when combined with Flucloxacillin. |
| Fluconazole | The serum concentration of Bosutinib can be increased when it is combined with Fluconazole. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Bosutinib. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Bosutinib. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bosutinib. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Bosutinib. |
| Flunisolide | The metabolism of Bosutinib can be increased when combined with Flunisolide. |
| Fluocinolone acetonide | The metabolism of Bosutinib can be increased when combined with Fluocinolone acetonide. |
| Fluocinonide | The metabolism of Bosutinib can be increased when combined with Fluocinonide. |
| Fluocortolone | The metabolism of Bosutinib can be increased when combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bosutinib. |
| Fluorouracil | The metabolism of Fluorouracil can be decreased when combined with Bosutinib. |
| Fluoxetine | The metabolism of Bosutinib can be decreased when combined with Fluoxetine. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bosutinib. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Bosutinib is combined with Fluprednisolone. |
| Fluticasone | The metabolism of Bosutinib can be increased when combined with Fluticasone. |
| Fluticasone furoate | The metabolism of Bosutinib can be increased when combined with Fluticasone furoate. |
| Fluticasone propionate | The metabolism of Bosutinib can be decreased when combined with Fluticasone propionate. |
| Fluvastatin | The metabolism of Fluvastatin can be decreased when combined with Bosutinib. |
| Fluvoxamine | The metabolism of Bosutinib can be decreased when combined with Fluvoxamine. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib. |
| Fondaparinux | The risk or severity of bleeding can be increased when Fondaparinux is combined with Bosutinib. |
| Formestane | The metabolism of Bosutinib can be increased when combined with Formestane. |
| Fosamprenavir | The metabolism of Bosutinib can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The metabolism of Bosutinib can be increased when combined with Fosaprepitant. |
| Fosnetupitant | The metabolism of Bosutinib can be decreased when combined with Fosnetupitant. |
| Fosphenytoin | The metabolism of Bosutinib can be increased when combined with Fosphenytoin. |
| Fostamatinib | The metabolism of Bosutinib can be decreased when combined with Fostamatinib. |
| Fostemsavir | The serum concentration of Bosutinib can be increased when it is combined with Fostemsavir. |
| Fusidic acid | The metabolism of Bosutinib can be decreased when combined with Fusidic acid. |
| Futibatinib | The serum concentration of Bosutinib can be increased when it is combined with Futibatinib. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Bosutinib. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bosutinib. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib. |
| Gilteritinib | The metabolism of Bosutinib can be decreased when combined with Gilteritinib. |
| Ginkgo biloba | The metabolism of Bosutinib can be decreased when combined with Ginkgo biloba. |
| Glasdegib | The serum concentration of Bosutinib can be increased when it is combined with Glasdegib. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Bosutinib. |
| Glecaprevir | The serum concentration of Bosutinib can be increased when it is combined with Glecaprevir. |
| Glyburide | The metabolism of Bosutinib can be decreased when combined with Glyburide. |
| Glycerol phenylbutyrate | The metabolism of Bosutinib can be increased when combined with Glycerol phenylbutyrate. |
| Golimumab | The metabolism of Bosutinib can be increased when combined with Golimumab. |
| Grazoprevir | The serum concentration of Bosutinib can be increased when it is combined with Grazoprevir. |
| Griseofulvin | The metabolism of Bosutinib can be increased when combined with Griseofulvin. |
| Hydrocortamate | The metabolism of Bosutinib can be increased when combined with Hydrocortamate. |
| Hydrocortisone | The metabolism of Bosutinib can be increased when combined with Hydrocortisone. |
| Hydrocortisone acetate | The metabolism of Bosutinib can be increased when combined with Hydrocortisone acetate. |
| Hydrocortisone butyrate | The metabolism of Bosutinib can be increased when combined with Hydrocortisone butyrate. |
| Hydrocortisone succinate | The metabolism of Bosutinib can be increased when combined with Hydrocortisone succinate. |
| Hydroflumethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Bosutinib. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Bosutinib. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bosutinib. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Bosutinib. |
| Ibuprofen | The metabolism of Ibuprofen can be decreased when combined with Bosutinib. |
| Ketamine | The metabolism of Ketamine can be decreased when combined with Bosutinib. |
| Ketazolam | The metabolism of Bosutinib can be decreased when combined with Ketazolam. |
| Ketoconazole | The serum concentration of Bosutinib can be increased when it is combined with Ketoconazole. |
| Ketorolac | The metabolism of Ketorolac can be decreased when combined with Bosutinib. |
| Lacosamide | The metabolism of Bosutinib can be decreased when combined with Lacosamide. |
| Lanreotide | The metabolism of Bosutinib can be decreased when combined with Lanreotide. |
| Lansoprazole | Lansoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lapatinib | The serum concentration of Bosutinib can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Bosutinib can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Bosutinib can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Bosutinib can be increased when it is combined with Ledipasvir. |
| Lefamulin | The serum concentration of Bosutinib can be increased when it is combined with Lefamulin. |
| Leflunomide | The risk or severity of adverse effects can be increased when Bosutinib is combined with Leflunomide. |
| Lemborexant | The serum concentration of Bosutinib can be increased when it is combined with Lemborexant. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bosutinib. |
| Lenvatinib | The serum concentration of Bosutinib can be increased when it is combined with Lenvatinib. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib. |
| Lesinurad | The metabolism of Bosutinib can be increased when combined with Lesinurad. |
| Letermovir | The metabolism of Bosutinib can be decreased when combined with Letermovir. |
| Levacetylmethadol | The metabolism of Levacetylmethadol can be decreased when combined with Bosutinib. |
| Levamlodipine | The serum concentration of Levamlodipine can be increased when it is combined with Bosutinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Bosutinib can be increased when it is combined with Levoketoconazole. |
| Levomilnacipran | The metabolism of Levomilnacipran can be decreased when combined with Bosutinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bosutinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Lidocaine. |
| Linagliptin | The serum concentration of Bosutinib can be increased when it is combined with Linagliptin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Bosutinib. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bosutinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Bosutinib. |
| Lipegfilgrastim | Bosutinib may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lomitapide | The serum concentration of Bosutinib can be increased when it is combined with Lomitapide. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Bosutinib. |
| Lonafarnib | The serum concentration of Bosutinib can be increased when it is combined with Lonafarnib. |
| Loncastuximab tesirine | The serum concentration of Bosutinib can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The metabolism of Loperamide can be decreased when combined with Bosutinib. |
| Lopinavir | The serum concentration of Bosutinib can be increased when it is combined with Lopinavir. |
| Lorlatinib | The serum concentration of Bosutinib can be decreased when it is combined with Lorlatinib. |
| Losartan | The metabolism of Bosutinib can be decreased when combined with Losartan. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Bosutinib. |
| Loxapine | The serum concentration of Bosutinib can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Bosutinib can be increased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Bosutinib can be increased when it is combined with Lusutrombopag. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Bosutinib. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Manidipine | The metabolism of Bosutinib can be decreased when combined with Manidipine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bosutinib. |
| Meprednisone | The metabolism of Bosutinib can be increased when combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bosutinib. |
| Mestranol | The metabolism of Mestranol can be decreased when combined with Bosutinib. |
| Metamizole | The risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib. |
| Methadone | The metabolism of Bosutinib can be decreased when combined with Methadone. |
| Methantheline | Methantheline can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methimazole | The metabolism of Bosutinib can be decreased when combined with Methimazole. |
| Methotrexate | The metabolism of Methotrexate can be decreased when combined with Bosutinib. |
| Methoxy polyethylene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bosutinib. |
| Methylene blue | The serum concentration of Bosutinib can be increased when it is combined with Methylene blue. |
| Methylergometrine | The metabolism of Bosutinib can be decreased when combined with Methylergometrine. |
| Methylphenobarbital | The metabolism of Bosutinib can be increased when combined with Methylphenobarbital. |
| Methylprednisolone | The metabolism of Bosutinib can be increased when combined with Methylprednisolone. |
| Methylprednisone | The metabolism of Bosutinib can be decreased when combined with Methylprednisone. |
| Methysergide | The metabolism of Bosutinib can be decreased when combined with Methysergide. |
| Metreleptin | The metabolism of Bosutinib can be increased when combined with Metreleptin. |
| Metronidazole | The metabolism of Bosutinib can be decreased when combined with Metronidazole. |
| Metyrapone | The metabolism of Bosutinib can be increased when combined with Metyrapone. |
| Miconazole | The metabolism of Bosutinib can be decreased when combined with Miconazole. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Bosutinib. |
| Midostaurin | The metabolism of Bosutinib can be decreased when combined with Midostaurin. |
| Mifepristone | The serum concentration of Bosutinib can be increased when it is combined with Mifepristone. |
| Milnacipran | The metabolism of Bosutinib can be decreased when combined with Milnacipran. |
| Miocamycin | The metabolism of Bosutinib can be decreased when combined with Miocamycin. |
| Mirabegron | The serum concentration of Bosutinib can be increased when it is combined with Mirabegron. |
| Mirtazapine | The metabolism of Bosutinib can be decreased when combined with Mirtazapine. |
| Mitapivat | The serum concentration of Bosutinib can be increased when it is combined with Mitapivat. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Bosutinib. |
| Mitotane | The metabolism of Bosutinib can be increased when combined with Mitotane. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bosutinib. |
| Mobocertinib | The serum concentration of Bosutinib can be decreased when it is combined with Mobocertinib. |
| Modafinil | The metabolism of Bosutinib can be increased when combined with Modafinil. |
| Moderna COVID-19 Vaccine | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bosutinib. |
| Modified vaccinia ankara | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bosutinib. |
| Mometasone furoate | The metabolism of Bosutinib can be increased when combined with Mometasone furoate. |
| Monomethyl fumarate | The risk or severity of adverse effects can be increased when Bosutinib is combined with Monomethyl fumarate. |
| Montelukast | The metabolism of Montelukast can be decreased when combined with Bosutinib. |
| Morphine | The metabolism of Morphine can be decreased when combined with Bosutinib. |
| Mosunetuzumab | The metabolism of Bosutinib can be decreased when combined with Mosunetuzumab. |
| Mumps virus strain | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bosutinib. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bosutinib. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bosutinib. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bosutinib. |
| Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Bosutinib. |
| Nafcillin | The metabolism of Bosutinib can be increased when combined with Nafcillin. |
| Naloxone | The metabolism of Bosutinib can be decreased when combined with Naloxone. |
| Naproxen | The metabolism of Naproxen can be decreased when combined with Bosutinib. |
| Natalizumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Natalizumab. |
| Nefazodone | The metabolism of Bosutinib can be decreased when combined with Nefazodone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Bosutinib. |
| Nelfinavir | The metabolism of Bosutinib can be decreased when combined with Nelfinavir. |
| Neratinib | The serum concentration of Bosutinib can be increased when it is combined with Neratinib. |
| Netupitant | The serum concentration of Bosutinib can be increased when it is combined with Netupitant. |
| Niacin | The metabolism of Bosutinib can be decreased when combined with Niacin. |
| Nicardipine | The metabolism of Bosutinib can be decreased when combined with Nicardipine. |
| Nilotinib | The serum concentration of Bosutinib can be increased when it is combined with Nilotinib. |
| Nilvadipine | The metabolism of Bosutinib can be decreased when combined with Nilvadipine. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Bosutinib. |
| Nintedanib | The metabolism of Bosutinib can be decreased when combined with Nintedanib. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethisterone | The metabolism of Bosutinib can be decreased when combined with Norethisterone. |
| Norgestimate | The serum concentration of Bosutinib can be increased when it is combined with Norgestimate. |
| Nortriptyline | The metabolism of Nortriptyline can be decreased when combined with Bosutinib. |
| Noscapine | The metabolism of Bosutinib can be decreased when combined with Noscapine. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bosutinib. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Obinutuzumab. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ocrelizumab. |
| Octreotide | The serum concentration of Bosutinib can be increased when it is combined with Octreotide. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ofatumumab. |
| Olanzapine | Olanzapine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Olaparib | The metabolism of Bosutinib can be decreased when combined with Olaparib. |
| Olodaterol | The metabolism of Olodaterol can be decreased when combined with Bosutinib. |
| Omadacycline | The serum concentration of Bosutinib can be increased when it is combined with Omadacycline. |
| Ombitasvir | The metabolism of Ombitasvir can be decreased when combined with Bosutinib. |
| Omeprazole | Omeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oritavancin | The metabolism of Bosutinib can be increased when combined with Oritavancin. |
| Orphenadrine | The metabolism of Bosutinib can be decreased when combined with Orphenadrine. |
| Osilodrostat | The metabolism of Bosutinib can be decreased when combined with Osilodrostat. |
| Osimertinib | The metabolism of Osimertinib can be decreased when combined with Bosutinib. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bosutinib. |
| Oxcarbazepine | The metabolism of Bosutinib can be increased when combined with Oxcarbazepine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Oxybuprocaine. |
| Oxybutynin | The metabolism of Bosutinib can be decreased when combined with Oxybutynin. |
| Ozanimod | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ozanimod. |
| Paclitaxel | The metabolism of Bosutinib can be increased when combined with Paclitaxel. |
| Pacritinib | The serum concentration of Bosutinib can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Bosutinib can be increased when it is combined with Palbociclib. |
| Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Bosutinib. |
| Paliperidone | The serum concentration of Bosutinib can be increased when it is combined with Paliperidone. |
| Panobinostat | The metabolism of Panobinostat can be decreased when combined with Bosutinib. |
| Pantoprazole | Pantoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Paramethadione | The metabolism of Paramethadione can be decreased when combined with Bosutinib. |
| Parathyroid hormone | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Bosutinib. |
| Paritaprevir | The serum concentration of Bosutinib can be increased when it is combined with Paritaprevir. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Bosutinib. |
| Pasireotide | The metabolism of Bosutinib can be decreased when combined with Pasireotide. |
| Pazopanib | The metabolism of Bosutinib can be decreased when combined with Pazopanib. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bosutinib. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Bosutinib is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bosutinib. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bosutinib. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bosutinib. |
| Peginterferon beta-1a | The risk or severity of adverse effects can be increased when Bosutinib is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bosutinib. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Bosutinib. |
| Pentobarbital | The metabolism of Bosutinib can be increased when combined with Pentobarbital. |
| Pentosan polysulfate | The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bosutinib. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Bosutinib. |
| Pentoxifylline | The risk or severity of bleeding can be increased when Pentoxifylline is combined with Bosutinib. |
| Perampanel | The metabolism of Bosutinib can be increased when combined with Perampanel. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bosutinib. |
| Pexidartinib | The metabolism of Pexidartinib can be decreased when combined with Bosutinib. |
| Phenindione | The risk or severity of bleeding can be increased when Phenindione is combined with Bosutinib. |
| Phenobarbital | The metabolism of Bosutinib can be increased when combined with Phenobarbital. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Phenol. |
| Phenprocoumon | The metabolism of Phenprocoumon can be decreased when combined with Bosutinib. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bosutinib. |
| Phenylbutazone | The metabolism of Bosutinib can be increased when combined with Phenylbutazone. |
| Phenytoin | The metabolism of Bosutinib can be increased when combined with Phenytoin. |
| Pibrentasvir | The serum concentration of Bosutinib can be increased when it is combined with Pibrentasvir. |
| Pimavanserin | The metabolism of Bosutinib can be decreased when combined with Pimavanserin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bosutinib. |
| Pimozide | The metabolism of Pimozide can be decreased when combined with Bosutinib. |
| Pioglitazone | The metabolism of Pioglitazone can be decreased when combined with Bosutinib. |
| Piperaquine | The metabolism of Bosutinib can be decreased when combined with Piperaquine. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bosutinib. |
| Piroxicam | The metabolism of Piroxicam can be decreased when combined with Bosutinib. |
| Pitavastatin | The metabolism of Pitavastatin can be decreased when combined with Bosutinib. |
| Pitolisant | The serum concentration of Bosutinib can be decreased when it is combined with Pitolisant. |
| Polythiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bosutinib. |
| Pomalidomide | The metabolism of Pomalidomide can be decreased when combined with Bosutinib. |
| Ponatinib | The serum concentration of Bosutinib can be increased when it is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ponesimod. |
| Posaconazole | The metabolism of Bosutinib can be decreased when combined with Posaconazole. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Bosutinib. |
| Potassium perchlorate | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Bosutinib. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Bosutinib is combined with Pralatrexate. |
| Pralsetinib | The serum concentration of Bosutinib can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Pramocaine. |
| Prasugrel | The risk or severity of bleeding can be increased when Prasugrel is combined with Bosutinib. |
| Pravastatin | The serum concentration of Bosutinib can be increased when it is combined with Pravastatin. |
| Prednisolone | The metabolism of Bosutinib can be increased when combined with Prednisolone. |
| Prednisolone acetate | The metabolism of Bosutinib can be increased when combined with Prednisolone acetate. |
| Prednisolone phosphate | The serum concentration of Bosutinib can be decreased when it is combined with Prednisolone phosphate. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Bosutinib. |
| Prednisone acetate | The metabolism of Bosutinib can be increased when combined with Prednisone acetate. |
| Pretomanid | The metabolism of Bosutinib can be decreased when combined with Pretomanid. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Prilocaine. |
| Primaquine | The metabolism of Bosutinib can be decreased when combined with Primaquine. |
| Primidone | The metabolism of Bosutinib can be increased when combined with Primidone. |
| Probenecid | The metabolism of Bosutinib can be increased when combined with Probenecid. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Procaine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Bosutinib. |
| Promethazine | Promethazine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propafenone | The serum concentration of Bosutinib can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Proparacaine. |
| Propofol | The metabolism of Bosutinib can be decreased when combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Propoxycaine. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Bosutinib. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Bosutinib. |
| Protein S human | The risk or severity of bleeding can be increased when Protein S human is combined with Bosutinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Bosutinib. |
| Prucalopride | The metabolism of Prucalopride can be decreased when combined with Bosutinib. |
| Quinidine | The serum concentration of Bosutinib can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Bosutinib can be increased when it is combined with Quinine. |
| Quinupristin | The metabolism of Bosutinib can be decreased when combined with Quinupristin. |
| Rabeprazole | Rabeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bosutinib. |
| Rabies antigen, A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bosutinib. |
| Rabies virus B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bosutinib. |
| Raloxifene | The metabolism of Bosutinib can be decreased when combined with Raloxifene. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bosutinib. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranolazine | The serum concentration of Bosutinib can be increased when it is combined with Ranolazine. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ravulizumab. |
| Regorafenib | The serum concentration of Bosutinib can be increased when it is combined with Regorafenib. |
| Relugolix | The serum concentration of Bosutinib can be increased when it is combined with Relugolix. |
| Remdesivir | The metabolism of Bosutinib can be decreased when combined with Remdesivir. |
| Repaglinide | The metabolism of Repaglinide can be decreased when combined with Bosutinib. |
| Reserpine | The serum concentration of Bosutinib can be increased when it is combined with Reserpine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Bosutinib. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Bosutinib. |
| Revefenacin | The serum concentration of Bosutinib can be increased when it is combined with Revefenacin. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Bosutinib. |
| Ribociclib | The metabolism of Bosutinib can be decreased when combined with Ribociclib. |
| Rifampicin | The serum concentration of Bosutinib can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Bosutinib can be increased when it is combined with Rifamycin. |
| Rifapentine | The metabolism of Bosutinib can be increased when combined with Rifapentine. |
| Rilonacept | The metabolism of Bosutinib can be increased when combined with Rilonacept. |
| Rilpivirine | The metabolism of Bosutinib can be decreased when combined with Rilpivirine. |
| Rimegepant | The serum concentration of Bosutinib can be increased when it is combined with Rimegepant. |
| Riociguat | The metabolism of Riociguat can be decreased when combined with Bosutinib. |
| Ripretinib | The serum concentration of Bosutinib can be increased when it is combined with Ripretinib. |
| Risankizumab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Risankizumab. |
| Ritonavir | The serum concentration of Bosutinib can be increased when it is combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bosutinib. |
| Rivaroxaban | The serum concentration of Bosutinib can be increased when it is combined with Rivaroxaban. |
| Rofecoxib | The metabolism of Bosutinib can be increased when combined with Rofecoxib. |
| Roflumilast | The serum concentration of Roflumilast can be increased when it is combined with Bosutinib. |
| Rolapitant | The serum concentration of Bosutinib can be increased when it is combined with Rolapitant. |
| Romidepsin | The metabolism of Romidepsin can be decreased when combined with Bosutinib. |
| Ropeginterferon alfa-2b | The risk or severity of adverse effects can be increased when Bosutinib is combined with Ropeginterferon alfa-2b. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Ropivacaine. |
| Rosiglitazone | The metabolism of Rosiglitazone can be decreased when combined with Bosutinib. |
| Rosuvastatin | The metabolism of Bosutinib can be decreased when combined with Rosuvastatin. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bosutinib. |
| Roxadustat | The metabolism of Roxadustat can be decreased when combined with Bosutinib. |
| Roxithromycin | The metabolism of Bosutinib can be decreased when combined with Roxithromycin. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bosutinib. |
| Rucaparib | The metabolism of Bosutinib can be decreased when combined with Rucaparib. |
| Rufinamide | The metabolism of Bosutinib can be increased when combined with Rufinamide. |
| Ruxolitinib | The metabolism of Ruxolitinib can be decreased when combined with Bosutinib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Bosutinib. |
| Sapropterin | The serum concentration of Bosutinib can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Bosutinib can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Bosutinib can be increased when it is combined with Sarecycline. |
| Sarilumab | The metabolism of Bosutinib can be increased when combined with Sarilumab. |
| Satralizumab | The serum concentration of Bosutinib can be decreased when it is combined with Satralizumab. |
| Secobarbital | The metabolism of Bosutinib can be increased when combined with Secobarbital. |
| Secukinumab | The metabolism of Bosutinib can be increased when combined with Secukinumab. |
| Selegiline | The metabolism of Selegiline can be decreased when combined with Bosutinib. |
| Selexipag | The metabolism of Selexipag can be decreased when combined with Bosutinib. |
| Selumetinib | The metabolism of Selumetinib can be decreased when combined with Bosutinib. |
| Sildenafil | The serum concentration of Bosutinib can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Bosutinib can be increased when it is combined with Silodosin. |
| Siltuximab | The metabolism of Bosutinib can be increased when combined with Siltuximab. |
| Simeprevir | The serum concentration of Bosutinib can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Bosutinib can be increased when it is combined with Simvastatin. |
| Siponimod | The metabolism of Siponimod can be decreased when combined with Bosutinib. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bosutinib. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Bosutinib. |
| Sitagliptin | The metabolism of Sitagliptin can be decreased when combined with Bosutinib. |
| Sitaxentan | The metabolism of Bosutinib can be decreased when combined with Sitaxentan. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bosutinib. |
| Sodium bicarbonate | Sodium bicarbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Bosutinib. |
| Sodium zirconium cyclosilicate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sofosbuvir | The serum concentration of Bosutinib can be increased when it is combined with Sofosbuvir. |
| Somatostatin | The metabolism of Bosutinib can be decreased when combined with Somatostatin. |
| Somatrogon | The metabolism of Bosutinib can be increased when combined with Somatrogon. |
| Sonidegib | The metabolism of Sonidegib can be decreased when combined with Bosutinib. |
| Sorafenib | The serum concentration of Bosutinib can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Bosutinib can be increased when it is combined with Sotagliflozin. |
| Sotorasib | The serum concentration of Bosutinib can be decreased when it is combined with Sotorasib. |
| Spesolimab | The risk or severity of adverse effects can be increased when Bosutinib is combined with Spesolimab. |
| St. John’s Wort | The serum concentration of Bosutinib can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The metabolism of Bosutinib can be decreased when combined with Stiripentol. |
| Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Bosutinib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Bosutinib. |
| Sulfadiazine | The metabolism of Sulfadiazine can be decreased when combined with Bosutinib. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bosutinib. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bosutinib. |
| Sulfinpyrazone | The metabolism of Bosutinib can be increased when combined with Sulfinpyrazone. |
| Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Bosutinib. |
| Sunitinib | The metabolism of Sunitinib can be decreased when combined with Bosutinib. |
| Suvorexant | The serum concentration of Bosutinib can be increased when it is combined with Suvorexant. |
| Tacrolimus | The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus. |
| Talazoparib | The serum concentration of Bosutinib can be increased when it is combined with Talazoparib. |
| Tamoxifen | The serum concentration of Bosutinib can be increased when it is combined with Tamoxifen. |
| Tasimelteon | The metabolism of Bosutinib can be decreased when combined with Tasimelteon. |
| Tazarotene | The metabolism of Tazarotene can be decreased when combined with Bosutinib. |
| Tazemetostat | The metabolism of Bosutinib can be decreased when combined with Tazemetostat. |
| Technetium Tc-99m sestamibi | The serum concentration of Bosutinib can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tecovirimat | The metabolism of Bosutinib can be increased when combined with Tecovirimat. |
| Tedizolid phosphate | The risk or severity of myelosuppression can be increased when Bosutinib is combined with Tedizolid phosphate. |
| Tegafur | The metabolism of Tegafur can be decreased when combined with Bosutinib. |
| Tegaserod | The serum concentration of Bosutinib can be increased when it is combined with Tegaserod. |
| Telaprevir | The serum concentration of Bosutinib can be increased when it is combined with Telaprevir. |
| Telithromycin | The metabolism of Bosutinib can be decreased when combined with Telithromycin. |
| Telotristat ethyl | The serum concentration of Bosutinib can be decreased when it is combined with Telotristat ethyl. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Bosutinib. |
| Temsirolimus | The serum concentration of Bosutinib can be increased when it is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Bosutinib. |
| Teniposide | The metabolism of Bosutinib can be decreased when combined with Teniposide. |
| Tenofovir alafenamide | The metabolism of Bosutinib can be decreased when combined with Tenofovir alafenamide. |
| Tenofovir disoproxil | The serum concentration of Bosutinib can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Bosutinib can be increased when it is combined with Tepotinib. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bosutinib. |
| Terbinafine | The metabolism of Bosutinib can be increased when combined with Terbinafine. |
| Terfenadine | The metabolism of Bosutinib can be decreased when combined with Terfenadine. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Bosutinib is combined with Teriflunomide. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Bosutinib. |
| Testosterone | The metabolism of Bosutinib can be increased when combined with Testosterone. |
| Testosterone cypionate | The metabolism of Testosterone cypionate can be decreased when combined with Bosutinib. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned
Pregnancy
This medication should not be taken during pregnancy. Bosutinib may cause severe harm to a developing baby if it is taken by the mother while she is pregnant. Female partners of men taking this medication should not become pregnant. Both women and men must use a reliable method of birth control (e.g., condoms, birth control pill) during treatment and for at least 4 weeks after treatment is finished. If you become pregnant while taking this medication, contact your doctor immediately.
Lactation
No information is available on the clinical use of bosutinib during breastfeeding. Because bosutinib is 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 22 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during bosutinib therapy and the manufacturer recommends withholding breastfeeding until 2 weeks following the last dose.
How should this medicine be used?
Bosutinib comes as a tablet to take by mouth. It is usually taken with food once a day. Take bosutinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bosutinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them. If any of the tablets are broken or crushed, do not touch them with your bare hands.
Your doctor may temporarily or permanently stop your treatment or adjust your dose of bosutinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take bosutinib even if you feel well. Do not stop taking bosutinib without talking to your doctor.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
What special precautions should I follow?
Before taking bosutinib,
- tell your doctor and pharmacist if you are allergic to bosutinib or any of the ingredients in bosutinib tablets. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antifungals such as ketoconazole and itraconazole (Sporanox); aprepitant (Emend); certain medications used to treat human immunodeficiency virus (HIV) such as indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Invirase); medications to reduce stomach acid (proton-pump inhibitors) such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), and rabeprazole (AcipHex); diltiazem (Cardizem, Cartia, Tiazac); erythromycin (E.E.S., E-Mycin, Erythrocin); nefazodone; rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane in Rifamate, in Rifater). Many other medications may also interact with bosutinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- if you are taking antacids, such as aluminum hydroxide/magnesium hydroxide (Maalox), calcium carbonate (Tums) or calcium carbonate and magnesium (Rolaids), or medications to reduce stomach acids, such as cimetidine (Tagamet), famotidine (Pepcid), or ranitidine (Zantac), take them 2 hours before or 2 hours after you take bosutinib.
- tell your doctor what herbal products you are taking, especially St. John’s wort.
- tell your doctor if you have or have ever had high blood pressure, diabetes, or kidney, liver, or heart disease.
- tell your doctor if you are pregnant or plan to become pregnant. You will need to take a pregnancy test before you start treatment and you should not become pregnant while you are taking bosutinib. You should use an effective form of birth control during treatment with bosutinib and for 2 weeks after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking bosutinib, call your doctor. Bosutinib may harm the fetus.
- tell your doctor if you are breastfeeding. You should not breastfeed while you are taking bosutinib and for 2 weeks after your last dose.
- you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of taking bosutinib.
References